ALG-097558
ALG-097558-702 / DMID 24-0001
Phase 1 small_molecule completed
Quick answer
ALG-097558 for COVID-19 is a Phase 1 program (small_molecule) at Aligos Therapeutics with 3 ClinicalTrials.gov record(s).
Program details
- Company
- Aligos Therapeutics
- Indication
- COVID-19
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- completed